BioLineRx (BLRX) Cash from Financing Activities (2013 - 2025)

BioLineRx's Cash from Financing Activities history runs 13 years deep, the most recent figure standing at -$1.3 million for Q4 2025.

• In Q4 2025, Cash from Financing Activities fell 12.89% year-over-year to -$1.3 million; the TTM figure through Dec 2025 stood at $8.9 million (down 56.99% YoY), while the FY2025 annual figure was $8.9 million, down 56.99% from the prior year.
• Cash from Financing Activities was -$1.3 million for Q4 2025 at BioLineRx, down from -$916000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $41.9 million in Q1 2021 to a low of -$1.3 million in Q4 2025.
• Historically, Cash from Financing Activities has averaged $6.1 million across 5 years, with a median of $62500.0 in 2021.
• Biggest YoY gain for Cash from Financing Activities was 17920.15% in 2024; the steepest drop was 1724.49% in 2024.
• A 5-year view of Cash from Financing Activities shows it stood at $174000.0 in 2021, then slumped by 471.84% to -$647000.0 in 2022, then jumped by 1914.53% to $11.7 million in 2023, then tumbled by 109.45% to -$1.1 million in 2024, then decreased by 12.89% to -$1.3 million in 2025.
• The last three Cash from Financing Activities figures came in at -$1.3 million (Q4 2025), -$916000.0 (Q3 2025), and $1.6 million (Q2 2025), per Business Quant data.